By Brazil Stock Guide – Oncoclínicas do Brasil (ONCO3) became one of the first publicly listed companies to quantify direct financial fallout from the Central Bank’s decision to place Banco Master S.A. and Banco Master de Investimento S.A. into extrajudicial liquidation on Tuesday. The intervention caused the full early maturity of R$433 million in bank deposit certificates (CDBs) issued by Master’s investment bank and held by the company.
Oncoclínicas noted that it had already provisioned R$217 million as of September 30, following a series of credit-rating downgrades in September and October, leaving an estimated net accounting exposure of R$216 million. The final impact will depend on the liquidation process and any recoveries under contractual safeguards.
Management said it will trigger all measures available under the Restructuring Instrument signed between the parties in October, including the exercise of a call option over stakes in Tessália FIP Multiestratégia and Quíron FIP Multiestratégia — funds that hold shares issued by Oncoclínicas and serve as collateral. Based on Monday’s closing price, these holdings are valued at roughly R$203 million.
The collapse of the Master group, which involved both its commercial and investment banking entities, represents one of the most far-reaching financial resolutions in recent years and has immediate repercussions for corporates with exposure to its credit. While part of the risk had already been provisioned, investors will monitor the efficiency of the recovery mechanisms and the progress of the liquidation led by the Central Bank’s appointed administrator.
Oncoclínicas stated it will continue evaluating the situation and adopt all legal and accounting measures required as the liquidation unfolds, adding that any incremental effects will depend on the regulator-guided process and the enforceability of contractual protections.
Leave a Reply